Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
Department of Medicine, Celiac Disease Center, Columbia University Irving Medical Center, New York, New York, USA.
Hematol Oncol. 2020 Aug;38(3):399-405. doi: 10.1002/hon.2720. Epub 2020 Feb 19.
Refractory celiac disease (RCD) is a rare condition associated with high morbidity that develops in individuals with celiac disease. It is known to be biologically heterogeneous, and currently two types are recognized based on immunophenotypic and molecular features, type I (RCD I) and type II (RCD II). Differentiating between RCD I and RCD II is critical, as patients with RCD II have substantially worse outcomes and a high risk of developing enteropathy-associated T-cell lymphoma. However, the current RCD classification is limited in scope, and atypical presentations and immunophenotypes are not recognized at present. Herein, we describe a unique case of RCD II with atypical clinical (primarily neurologic manifestations and lack of significant gastrointestinal symptoms), histopathologic (no villous atrophy), immunophenotypic (virtual absence of cytoplasmic CD3 expression), and molecular features (absence of clonal TR rearrangement and identification of pathogenic STAT3 and KMT2D mutations). This case highlights limitations of the current RCD classification system and the utility of next generation sequencing (NGS) studies in the diagnostic workup of RCD. Future algorithms need to recognize extraintestinal manifestations and incorporate atypical histopathologic and immunophenotypic features, as well as results of NGS analysis for RCD II classification.
难治性乳糜泻(RCD)是一种与高发病率相关的罕见疾病,发生在乳糜泻患者中。它被认为具有生物学异质性,目前根据免疫表型和分子特征,将其分为两型,即 I 型(RCD I)和 II 型(RCD II)。区分 RCD I 和 RCD II 至关重要,因为 RCD II 患者的预后明显更差,发生肠病相关 T 细胞淋巴瘤的风险较高。然而,目前的 RCD 分类范围有限,目前尚未认识到不典型表现和免疫表型。在此,我们描述了一例独特的 RCD II 病例,其临床表现(主要为神经系统表现,缺乏明显的胃肠道症状)、组织病理学(无绒毛萎缩)、免疫表型(细胞浆 CD3 表达几乎缺失)和分子特征(无克隆性 TR 重排,鉴定出致病性 STAT3 和 KMT2D 突变)均不典型。该病例凸显了当前 RCD 分类系统的局限性,以及下一代测序(NGS)研究在 RCD 诊断中的应用价值。未来的算法需要识别肠外表现,并纳入不典型的组织病理学和免疫表型特征,以及 NGS 分析结果,以进行 RCD II 分类。